Prosecution Insights
Last updated: November 20, 2026
Application No. 18/714,020

METHOD FOR PRODUCING DISACCHARIDE USING BETA-GLUCOSIDASE AND COFACTOR THEREOF AND COMPOSITION FOR INDUCING ENZYME PRODUCTION OF STRAIN OF GENUS TRICHODERMA COMPRISING PRODUCED DISACCHARIDE

Non-Final OA §102
Filed
May 28, 2024
Priority
Nov 30, 2021 — RE 10-2021-0168330 +2 more
Examiner
OLSON, ANDREA STEFFEL
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
CJ CheilJedang Corporation
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
8m
Est. Remaining
51%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
897 granted / 1434 resolved
+2.6% vs TC avg
Minimal -12% lift
Without
With
+-11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
61 currently pending
Career history
1510
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
37.5%
-2.5% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
22.9%
-17.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1434 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action This application is a national stage application of PCT/KR2022/019160, filed November 30, 2022, which claims priority to foreign applications 10-2021-0168330, filed November 30, 2021, and KR10-2021-0168329, filed November 30, 2021. Claims 1-18 are pending in this application. Applicant’s preliminary amendment submitted September 28, 2026, is acknowledged wherein claims 11 and 15 are amended. Election/Restrictions Applicant’s provisional election without traverse of group I, claims 1-10, drawn to a composition comprising 1-hydroxyglucitol-D-glucopyranoside, filed September 28, 2026, is acknowledged. Claims 11-18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-10 are pending in this application and examined on the merits herein. Claim Objections Claim 2 is objected to because of the following informalities: The claim refers to the compound (1S)-1-hydroglucitol-D-glucopyranoside, which appears to be the result of a typographical error. The intended f=chemical name appears to be (1S)-1-hydroxyglucitol-D-glucopyranoside Appropriate correction is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 3-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wang et al. (Reference included with PTO-892) Independent claim 1 is directed to a composition comprising (1S)-1-hydroglucitol-D-glucopyranoside or an isomer thereof. Wang et al. discloses a disaccharide compound fitting this chemical name, (p. 370 figure 4 compound 1) thereby anticipating claim 1. Furthermore the compound is disclosed as a purified product containing no additional components such as monosaccharides, thereby anticipating present claims 1 and 8-10. Regarding claims 4-7, these claims describe intended uses of the compound, but do not contain further structural limitations that would necessarily limit the actual structural composition of the claimed product. Therefore they do not further differentiate the claimed composition from the pure compound described by Wang. Regarding claim 3, the compound is produced by fermentation of a fungus in a culture medium comprising 20g/L maltose. (p. 367 left column second paragraph) Therefore the unpurified culture medium would anticipate claim 3. Conclusion Claims 1 and 3-10 are rejected. Claim 2 is objected to for depending from a rejected base claim but would be allowable if rewritten in independent form incorporating all the limitations of the rejected base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREA OLSON whose telephone number is (571)272-9051. The examiner can normally be reached M-F 6am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREA OLSON/ Primary Examiner, Art Unit 1693 10/27/2026
Read full office action

Prosecution Timeline

May 28, 2024
Application Filed
Nov 06, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797407
SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEM
5y 1m to grant Granted Nov 17, 2026
Patent 12799473
PORTABLE DEVICE FOR ISOLATING NUCLEIC ACID FROM BLOOD
3y 4m to grant Granted Nov 17, 2026
Patent 12788807
PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN
3y 8m to grant Granted Nov 10, 2026
Patent 12790447
METHOD FOR PREPARING ACYLATED CROSSLINKED GLYCOSAMINOGLYCANS
2y 8m to grant Granted Nov 10, 2026
Patent 12780951
METHOD FOR PRODUCING CATIONIZED CELLULOSE AND CATIONIZED CELLULOSE
4y 5m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
51%
With Interview (-11.9%)
3y 1m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1434 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month